Insider Trading Alert - DGICA, MEET And EXAC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Donegal Group (DGICA) - FREE Research Report

Donegal Mutual Insurance Co, who is 10% Owner at Donegal Group, bought 72 shares at $15.11 on May 19, 2015. Following this transaction, the 10% Owner owned 8.1 million shares meaning that the stake was boosted by 0% with the 72-share transaction.

The shares most recently traded at $14.61, down $0.50, or 3.44% since the insider transaction. Historical insider transactions for Donegal Group go as follows:

  • 4-Week # shares bought: 370,000
  • 12-Week # shares bought: 371,335
  • 24-Week # shares bought: 375,000

The average volume for Donegal Group has been 17,600 shares per day over the past 30 days. Donegal Group has a market cap of $329.1 million and is part of the financial sector and insurance industry. Shares are down 8.26% year-to-date as of the close of trading on Tuesday.

Donegal Group Inc., an insurance holding company, provides property and casualty insurance to businesses and individuals in the Mid-Atlantic, Midwestern, New England, and southern states. The stock currently has a dividend yield of 3.6%. The company has a P/E ratio of 18.3. Currently, there are no analysts who rate Donegal Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGICA - FREE

TheStreet Quant Ratings rates Donegal Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Donegal Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MeetMe (MEET) - FREE Research Report

Cook Geoffrey, who is Chief Executive Officer at MeetMe, sold 30,000 shares at $1.64 on May 19, 2015. Following this transaction, the Chief Executive Officer owned 2.0 million shares meaning that the stake was reduced by 1.45% with the 30,000-share transaction.

The shares most recently traded at $1.65, up $0.01, or 0.87% since the insider transaction. Historical insider transactions for MeetMe go as follows:

  • 4-Week # shares bought: 336,927
  • 4-Week # shares sold: 28,746
  • 12-Week # shares bought: 336,927
  • 12-Week # shares sold: 111,012
  • 24-Week # shares bought: 342,927
  • 24-Week # shares sold: 171,012

The average volume for MeetMe has been 309,400 shares per day over the past 30 days. MeetMe has a market cap of $73.2 million and is part of the technology sector and internet industry. Shares are up 6.54% year-to-date as of the close of trading on Tuesday.

MeetMe, Inc. owns and operates a social network for meeting new people on the Web and on mobile platforms in the United States. Currently, there are 3 analysts who rate MeetMe a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MEET - FREE

TheStreet Quant Ratings rates MeetMe as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including poor profit margins and a generally disappointing performance in the stock itself. Get the full MeetMe Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exactech (EXAC) - FREE Research Report

Watts Fern, who is Director at Exactech, sold 2,200 shares at $21.21 on May 19, 2015. Following this transaction, the Director owned 4,414 shares meaning that the stake was reduced by 33.26% with the 2,200-share transaction.

The shares most recently traded at $21.63, up $0.42, or 1.94% since the insider transaction. Historical insider transactions for Exactech go as follows:

  • 4-Week # shares bought: 738
  • 4-Week # shares sold: 6,500
  • 12-Week # shares bought: 738
  • 12-Week # shares sold: 6,500
  • 24-Week # shares bought: 738
  • 24-Week # shares sold: 6,500

The average volume for Exactech has been 43,500 shares per day over the past 30 days. Exactech has a market cap of $300.9 million and is part of the health care sector and health services industry. Shares are down 8.87% year-to-date as of the close of trading on Tuesday.

Exactech, Inc. develops, manufactures, markets, distributes, and sells orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally. The company has a P/E ratio of 18.4. Currently, there is 1 analyst who rates Exactech a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXAC - FREE

TheStreet Quant Ratings rates Exactech as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Exactech Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Insider Trading Alert - LDR, MBRG And DGICA Traded By Insiders

Insider Trading Alert - LDR, MBRG And DGICA Traded By Insiders

3 Stocks Pushing The Insurance Industry Lower

3 Stocks Pushing The Insurance Industry Lower

Insider Trading Alert - DGICA, TRC And SCX Traded By Insiders

Insider Trading Alert - DGICA, TRC And SCX Traded By Insiders

Insider Trading Alert - CNBKA, HMST And DGICA Traded By Insiders

Insider Trading Alert - CNBKA, HMST And DGICA Traded By Insiders